Among the emerging molecular drivers of aggressive prostate cancer, human epidermal growth factor receptor 2 (HER2) has gained increasing attention for its established roles in tumorigenesis, metastasis, and treatment resistance, as evidenced in cancers such as breast and gastric malignancies (4–6). This evidence concerns the gene ERBB2 and prostate carcinoma.